Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

28.00 +0.50 (+1.82%)
Official Closing Price Updated: 4:10 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
From Pfizer Inc.
Via Business Wire
News headline image
D-Wave Quantum vs. Rigetti Computing: Which Cutting Edge Quantum Stock Is a Better Buy in 2026? ↗
D-Wave is growing revenue at nearly 180% while Rigetti trades at a lower valuation, but both burn cash heavily and face unproven commercial roadmaps. 
Via The Motley Fool
Topics Supply Chain
News headline image
Warren Buffett's Favorite Valuation Indicator Blew Past the Level He Warned Was "Playing With Fire." Here Are 3 Stocks Still Cheap Enough to Buy. ↗
Buffett thinks many stocks are too hot to touch right now, but these three aren't. 
Via The Motley Fool
Topics Artificial Intelligence Energy
News headline image
1 Healthcare Stock with Competitive Advantages and 2 We Find Risky
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
News headline image
3 of the Best Dividend Stocks to Buy in October 2026 ↗
A couple of the stocks on this list pay more than 6% in dividends. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Pfizer Declares Fourth-Quarter 2026 Dividend
From Pfizer Inc.
Via Business Wire
News headline image
2 Unpopular Stocks That Should Get More Attention and 1 Facing Challenges
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
News headline image
Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock ↗
The healthcare stock's elevated valuation bakes in high expectations, leaving little room for error. 
Via The Motley Fool
News headline image
Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now ↗
Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study ↗
Vaxcyte stock catapulted Monday after its pneumococcal vaccine proved it's not inferior to shots from Pfizer and Merck. 
Via Investor's Business Daily
News headline image
Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend... 
Via The Motley Fool
Topics Intellectual Property
News headline image
Got $10,000 to Invest in October? These Stocks Could Generate Over $634 in Annual Income. ↗
Put your money to work generating dividend income with these stocks. 
Via The Motley Fool
News headline image
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? ↗
Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future. 
Via The Motley Fool
News headline image
Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield ↗
The crowd is looking at the next couple of years. It should be looking five years into the future. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Dirt Cheap Dividend Stocks Worth Buying in October ↗
There are blazing deals for some of the top healthcare stocks -- companies with proven track records and dividend yields as high as 6%. 
Via The Motley Fool
Topics Intellectual Property
News headline image
My 3 Favorite Ultra-High-Yield Dividend Stocks to Buy for October ↗
These stocks offer juicy yields and attractive risk-reward profiles. 
Via The Motley Fool
Topics Artificial Intelligence Economy Energy
News headline image
3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note ↗
With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%. 
Via MarketBeat
Topics Bonds Retirement
News headline image
Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? ↗
Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP ↗
VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings. 
Via The Motley Fool
Topics ETFs
News headline image
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
Novo Nordisk boasts a 33% net margin and fortress balance sheet, while Pfizer trades cheaper but faces major patent cliffs through 2030. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
From Pfizer Inc
Via Business Wire
News headline image
Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk. ↗
Pfizer has been going through a period of transition. 
Via The Motley Fool
Topics Earnings
News headline image
Kevin Warsh's Inflation Stance Makes These Cheap Dividend Stocks Look a Lot More Attractive ↗
Inflation is running hot, and the Fed is raising interest rates, but consumers aren't likely to pull back on the products these companies sell. 
Via The Motley Fool
Topics Economy
News headline image
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases,... 
Via MarketBeat
Topics ETFs
News headline image
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
From Pfizer Inc.
Via Business Wire
News headline image
With the Market Flashing Warning Signs Not Seen Since the Dot-Com Bust, Is Pfizer's 6% Yield a Safe Haven or a Trap? ↗
While Pfizer's dividend looks like a trap, its strong balance sheet and low valuation make it safer. 
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
Here Are My Top 2 High-Yield Healthcare Stocks to Buy Now ↗
Pfizer and Bristol Myers Squibb pair big dividends with growing drug pipelines, a rare combination for income-focused pharma investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
From Pfizer Inc.
Via Business Wire
News headline image
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗
Wall Street expects an even bigger rebound for this beaten-down biotech stock. 
Via The Motley Fool
News headline image
5 Dividend Stocks Yielding Over 5% With Fortress Financial Profiles to Buy Now ↗
These high-yielding stocks offer very durable dividends. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.